NICE has issued its final guidance recommending Vazkepa for reimbursement & use in the NHS in England and Wales to reduce the risk of major CV events in high-risk statin-treated patients with eCVD who have elevated triglycerides & eCVD. The product will be available on all local NHS formularies within 90 & 60 days
Final guidance also provides additional evidence that Amarin is successfully implementing its EU growth strategy & maximize the product’s international revenue outside of the US. The product is expected to be available across a territory in the coming mos.
Vazkepa is expected to be available in ~6 EU countries in 2022. The company will secure pricing decisions in ~8 countries & advance the reimbursement conversations in other EU markets
Ref: GlobalNeweswire | Image: Amarin
